Conference Coverage

Billing Errors Reduce Revenue and Work RVUs

San Diego—Incorrect documentation and billing led to substantial loss in gross revenue and relative value units (RVUs) in an academic nephrology setting. That was among the findings of an analysis conducted recently by Leslie P. Wong, MD, and Emilio P. Poggio, MD, at the Cleveland Clinic, Cleveland, Ohio. Analysis results were reported during a poster session at Kidney Week 2015 ... Read More »

Appropriate Frequency of Antibody Monitoring in CKD Patients

San Diego—In a study of patients with chronic kidney disease (CKD) who are at risk for hepatitis B virus infection, protective antibody levels were maintained in 95% of those monitored for 2 years. Ravindra Mukkunda, MD, and Zahra Jabir, MD, reported results of the study during a poster session at Kidney Week 2015. The poster was titled Monitoring of Protective ... Read More »

Pill Burden Lessened with Treatment with Sucroferric Oxyhydroxide

Hyperphosphatemia Update San Diego—Patients on maintenance hemodialysis may have difficulty maintaining target levels of serum phosphorous. In the United States, 40% of hemodialysis patients do not maintain serum phosphorous within target range. Risk of mortality is increased with elevations in serum phosphorous and with high levels of calcium ´ phosphorous product in this patient population. Treatment with a phosphate binder ... Read More »

Predictive Value of Pathologic Evaluation of Non-Tumor Renal Tissue

American Urological Association Quebec City—Valuable predictive information on post-operative renal function can be gathered via evaluation of non-tumor renal tissue at the time of radical nephrectomy. That was the primary finding of a study conducted by Adiel Mamut, BSc, MD, and colleagues at the Western University, department of surgery, division of urology, in London, Ontario. The researchers presented results of ... Read More »

Sucroferric Oxyhydroxide Safe and Well-Tolerated in the Long-Term

San Diego—In hemodialysis patients in Japan, PA21 (sucroferric oxyhydroxide [SFOH]) was well tolerated in the long term and had a low pill burden. That was among the findings of an open-label, multicenter study conducted in Japan to assess the long-term safety and efficacy of SFOH following a 52-week treatment period. Fumihiko Koiwa, MD, PhD, and colleagues presented results of the ... Read More »

Sevelamer Improves Oxidative Stress in Hemodialysis Patients

San Diego—Oxidative stress was improved in patients on maintenance hemodialysis with the use of sevelamer hydrochloride in a study conducted recently by Siren Sezer, MD, and colleagues. Study results were presented during a poster session at Kidney Week 2015 in a poster titled Sevelamer Hydrochloride Improves Oxidative Stress in Maintenance Hemodialysis Patients. Oxidative stress has an important role in the ... Read More »

Long Dialysis Recovery Time and Fluid Management

San Diego—A large proportion of patients on conventional hemodialysis face long dialysis recovery time, which is associated with increased mortality and shorter time to hospitalization. Wael F. Hussein, MD, and colleagues recently conducted a study to examine the association of fluid management and hemodynamics with recovery time in conventional hemodialysis patients. The researchers reported results of the study during a ... Read More »

Enzyme Replacement Therapy in Older Patients with Fabry Disease

San Diego—Despite enzyme replacement therapy, older patients in Canada with Fabry disease experience clinical events but seem to be living longer. That was among the findings of a comparison of outcomes of enzyme replacement therapy in patients >65 years of age compared with the overall Canadian Fabry Disease Initiative (CFDI) population. Michael L. West, BSc, FRCPC, FACP, and colleagues reported ... Read More »

Patient-Centric Automated Peritoneal Dialysis Cycler Rated Higher than Conventional Cycler

San Diego—Automated peritoneal dialysis (APD), a therapy for patients with end-stage renal disease (ESRD), is currently underutilized, due perhaps to the perception that patients may not be able to manage treatment setups, a skill required with that treatment modality. Some barriers to uptake of APD many be reduced via improvements to cycler technology that may futher simplify therapy procedures for ... Read More »

AMG 416 Safe after Discontinuation of Cinacalcet

San Diego—Significant decreases in parathyroid hormone (PTH) with no increase in serum phosphate or in albumin-adjusted serum calcium have been shown in two previous 26-week placebo-controlled randomized clinical trials with AMG 416, a novel intravenous calcimimetic agent. Kenneth Liss, DO, and colleagues recently conducted a 4-week, multiple-dose single-arm, open-label safety study designed to assess the incidence of hypocalcemia in patients ... Read More »